Key Developments: Actelion Ltd (ATLN.VX)

ATLN.VX on Virt-X Level 1

24 Apr 2015
Change (% chg)

CHF2.90 (+2.34%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Actelion Ltd comments on FY 2015 outlook
Tuesday, 21 Apr 2015 01:01am EDT 

Actelion Ltd:Strong performance drives FY 2015 financial guidance upgrade - now expecting low double-digit percentage core earnings growth at CER.  Full Article

Actelion says wins Japanese approval for heart and lung drug
Thursday, 26 Mar 2015 02:00am EDT 

Actelion Ltd:Japanese health regulator approved Opsumit, its new treatment for pulmonary arterial hypertension (PAH).  Full Article

Actelion Ltd announces commencement of share repurchase program
Sunday, 22 Mar 2015 08:00pm EDT 

Actelion Ltd:Announces commencement of share repurchase program.Has received approval from relevant authorities to launch repurchase of up to 10 million shares (8.76 pct of currently issued capital), over three years.  Full Article

Actelion says New Drug Application for selexipag (Uptravi) is accepted by FDA
Tuesday, 3 Mar 2015 11:35am EST 

Actelion Ltd:Actelion's New Drug Application for selexipag (Uptravi) is accepted by the U.S. FDA with a standard review time.  Full Article

Actelion Ltd gives FY 2015 earnings outlook - Conference Call
Monday, 16 Feb 2015 08:00am EST 

Actelion Ltd:Expects 2015 core earnings to grow in the low single-digit percentage range.  Full Article

Actelion Ltd to propose dividend
Monday, 16 Feb 2015 01:00am EST 

Actelion Ltd:Will recommend that shareholders approve a dividend of 1.30 Swiss francs per share, an increase of 8 percent.  Full Article

Actelion Ltd submits selexipag for EMA marketing authorisation in patients with pulmonary arterial hypertension
Monday, 1 Dec 2014 06:00pm EST 

Actelion Ltd:Announces submission of centralized Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for selexipag (Uptravi) in treatment of pulmonary arterial hypertension (PAH).Says submissions to US Food and Drug Administration and other territories are forthcoming.  Full Article

Actelion Ltd raises FY 2014 core earnings outlook
Tuesday, 21 Oct 2014 01:00am EDT 

Actelion Ltd:Now expects FY 2014 core earnings growth to be in the low twenties percentage range at constant exchange rates.Previously guided for FY 2014 core earnings to increase in at least mid-teens percentage range.  Full Article

Actelion Ltd announces that Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hypertension
Sunday, 15 Jun 2014 07:00pm EDT 

Actelion Ltd:Announces top-line results of pivotal Phase III GRIPHON study in 1,156 patients with pulmonary arterial hypertension (PAH) with selexipag, first selective oral prostacyclin IP receptor agonist.Initial analysis shows that the event-driven outcome study has met its primary efficacy endpoint with high statistical significance.Selexipag decreased risk of a morbidity/mortality event versus placebo by 39 pct. (p <0.0001).Efficacy observed was consistent across the key subgroups; age, gender, WHO Functional Class, PAH etiology and background PAH therapy.Patients were treated for up to 4.3 years.Overall tolerability profile of selexipag in GRIPHON was consistent with prostacyclin therapies.  Full Article

Actelion Ltd gives FY 2014 and FY 2015 core earnings outlook
Wednesday, 16 Apr 2014 08:00pm EDT 

Actelion Ltd:Expects core earnings (core operating income) growth in low-single digit range for FY 2014.Expects FY 2015 core earnings to grow in single-digit percentage range.FY 2013 core earnings of 619 million Swiss francs.  Full Article

European shares get earnings lift, Greece lags

LONDON, April 21 - Positive company earnings updates pushed European shares higher on Tuesday, with the Greek stock market a standout loser as worries mounted about its banking sector.

Search Stocks